Arcutis Biotherapeutics Inc reports results for the quarter ended in September - Earnings Summary

Arcutis Biotherapeutics

03/11/2023 12:54

* Arcutis Biotherapeutics Inc  ARQT.OQ  reported a quarterly
adjusted loss of 73 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of $-1.89.  The mean expectation of
eight analysts for the quarter was for a loss of 86 cents per
share. Wall Street expected results to range from $-1.30 to -55
cents per share.
    * Revenue rose 5,156.4% to $38.11 million from a year ago;
analysts expected $32.83 million. 
    * Arcutis Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 73 cents​.
    * The company reported a quarterly loss of $44.77 million.
    * Arcutis Biotherapeutics Inc shares had fallen by 58.2%
this
quarter and lost 85.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 29.3%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Arcutis
Biotherapeutics Inc is $33.00 

This summary was machine generated from LSEG data November 3 at
12:54 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.86          -0.73          Beat
 Jun. 30 2023      -1.25          -1.16          Beat
 Mar. 31 2023      -1.28          -1.31          Missed
 Dec. 31 2022      -1.42          -1.18          Beat